Tempus AI PE Ratio 2023-2024 | TEM
Current and historical p/e ratio for Tempus AI (TEM) from 2023 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Tempus AI PE ratio as of November 20, 2024 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Tempus AI PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2024-11-19 | 53.97 | inf | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $8.497B | $0.321B |
| Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inspire Medical Systems (INSP) | United States | $5.276B | 164.53 |
| Hims & Hers Health (HIMS) | United States | $5.141B | 130.72 |
| Privia Health (PRVA) | United States | $2.533B | 211.10 |
| Enovis (ENOV) | United States | $2.529B | 17.15 |
| IRhythm Technologies (IRTC) | United States | $2.362B | 0.00 |
| Azenta (AZTA) | United States | $2.001B | 99.78 |
| Omnicell (OMCL) | United States | $1.964B | 64.26 |
| Clover Health Investments (CLOV) | United States | $1.644B | 0.00 |
| 10x Genomics (TXG) | United States | $1.643B | 0.00 |
| Schrodinger (SDGR) | United States | $1.378B | 0.00 |
| Phreesia (PHR) | United States | $1.072B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.650B | 0.00 |
| Standard BioTools (LAB) | United States | $0.562B | 0.00 |
| Talkspace (TALK) | United States | $0.522B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.520B | 0.00 |
| Definitive Healthcare (DH) | United States | $0.483B | 83.60 |
| Health Catalyst (HCAT) | United States | $0.459B | 0.00 |
| TruBridge (TBRG) | United States | $0.244B | 71.22 |
| Pulmonx (LUNG) | United States | $0.237B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.214B | 0.00 |
| American Well (AMWL) | United States | $0.122B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.107B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.075B | 0.00 |
| HeartBeam (BEAT) | United States | $0.067B | 0.00 |
| 111 (YI) | China | $0.053B | 0.00 |
| CareCloud (CCLD) | United States | $0.046B | 0.00 |
| Zepp Health (ZEPP) | China | $0.040B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.040B | 0.00 |
| Outset Medical (OM) | United States | $0.039B | 0.00 |
| Movano (MOVE) | United States | $0.020B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.019B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.014B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.013B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.012B | 0.00 |
| MSP Recovery (LIFW) | United States | $0.010B | 0.00 |
| Precipio (PRPO) | United States | $0.009B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.006B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.004B | 0.00 |
| Syra Health (SYRA) | United States | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.002B | 0.00 |
| Zhongchao (ZCMD) | China | $0.002B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.000B | 0.00 |